BACKGROUND: The French @entity120 ( @entity120 ) registry allows the survey of epidemiological trends. Isolated cases of precapillary @entity120 have been reported in @entity1 who have @entity1860 treated with the @entity669 kinase inhibitor @entity8947 . METHODS AND RESULTS: This study was designed to describe incident cases of @entity8947 -associated @entity120 reported in the French @entity120 registry. From the approval of @entity8947 (November 2006) to September 30, 2010, 9 incident cases treated by @entity8947 at the time of @entity120 diagnosis were identified. At diagnosis, @entity1 had moderate to severe precapillary @entity120 with functional and @entity73 . No other incident @entity120 cases were exposed to other @entity669 kinase inhibitors at the time of @entity120 diagnosis. Clinical, functional, or hemodynamic improvements were observed within 4 months of @entity8947 discontinuation in all but 1 @entity1 . Three @entity1 required @entity120 treatment with endothelin receptor antagonist (n=2) or @entity460 channel blocker (n=1). After a median follow-up of 9 months (min-max 3-36), the majority of @entity1 did not demonstrate complete clinical and hemodynamic recovery, and no @entity1 reached a normal value of mean pulmonary artery pressure ( <=20 mm Hg). Two @entity1 (22%) died at follow-up (1 of unexplained @entity944 and 1 of @entity712 in the context of @entity295 , respectively, 8 and 12 months after @entity8947 withdrawal). The lowest estimate of incident @entity120 occurring in @entity1 exposed to @entity8947 in France was 0.45%. CONCLUSIONS: @entity8947 may induce severe precapillary @entity120 fulfilling the criteria of @entity120 , thus suggesting a direct and specific effect of @entity8947 on pulmonary vessels. Improvement is usually observed after withdrawal of @entity8947 .

Pulmonary arterial hypertension in XXXX treated by @entity8947 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity8947 :: ('MESH:C488369', 'Chemical') :: ['Dasatinib', 'dasatinib'] @entity712 :: ('MESH:D006333', 'Disease') :: ['cardiac failure'] @entity295 :: ('MESH:D018805', 'Disease') :: ['septicemia'] @entity944 :: ('MESH:D003645', 'Disease') :: ['sudden death'] @entity73 :: ('MESH:D003072', 'Disease') :: ['hemodynamic impairment'] @entity120 :: ('MESH:D006976', 'Disease') :: ['pulmonary hypertension', 'pulmonary arterial hypertension', 'PH'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium'] @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine'] @entity1860 :: ('MESH:D015464', 'Disease') :: ['chronic myelogenous leukemia']
@entity1 :: (9606,Species) :: ['patients']
